<pmc-articleset>
  <article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4">
    <!--The publisher of this article does not allow downloading of the full text in XML form.-->
    <front>
      <journal-meta>
        <journal-id journal-id-type="nlm-ta">N Engl J Med</journal-id>
        <journal-id journal-id-type="iso-abbrev">N. Engl. J. Med.</journal-id>
        <journal-id journal-id-type="pmc-domain-id">319</journal-id>
        <journal-id journal-id-type="pmc-domain">nihpa</journal-id>
        <journal-title-group>
          <journal-title>The New England journal of medicine</journal-title>
        </journal-title-group>
        <issn pub-type="ppub">0028-4793</issn>
        <issn pub-type="epub">1533-4406</issn>
        <custom-meta-group>
          <custom-meta>
            <meta-name>pmc-is-collection-domain</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-collection-title</meta-name>
            <meta-value>NIHPA Author Manuscripts</meta-value>
          </custom-meta>
        </custom-meta-group>
      </journal-meta>
      <article-meta>
        <article-id pub-id-type="pmcid">PMC4315319</article-id>
        <article-id pub-id-type="pmcid-ver">PMC4315319.1</article-id>
        <article-id pub-id-type="pmcaid">4315319</article-id>
        <article-id pub-id-type="pmcaiid">4315319</article-id>
        <article-id pub-id-type="manuscript-id">NIHMS650831</article-id>
        <article-id pub-id-type="pmid">25409260</article-id>
        <article-id pub-id-type="doi">10.1056/NEJMoa1406498</article-id>
        <article-id pub-id-type="manuscript-id-alternative">NIHMS650831</article-id>
        <article-id pub-id-type="manuscript-id-alternative">NIHPA650831</article-id>
        <article-version article-version-type="pmc-version">1</article-version>
        <article-categories>
          <subj-group subj-group-type="heading">
            <subject>Article</subject>
          </subj-group>
        </article-categories>
        <title-group>
          <article-title>Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma</article-title>
        </title-group>
        <contrib-group>
          <contrib contrib-type="author" equal-contrib="yes">
            <name name-style="western">
              <surname>Snyder</surname>
              <given-names initials="A">Alexandra</given-names>
            </name>
            <degrees>M.D.</degrees>
          </contrib>
          <contrib contrib-type="author" equal-contrib="yes">
            <name name-style="western">
              <surname>Makarov</surname>
              <given-names initials="V">Vladimir</given-names>
            </name>
            <degrees>M.D.</degrees>
          </contrib>
          <contrib contrib-type="author" equal-contrib="yes">
            <name name-style="western">
              <surname>Merghoub</surname>
              <given-names initials="T">Taha</given-names>
            </name>
            <degrees>Ph.D.</degrees>
          </contrib>
          <contrib contrib-type="author" equal-contrib="yes">
            <name name-style="western">
              <surname>Yuan</surname>
              <given-names initials="J">Jianda</given-names>
            </name>
            <degrees>M.D., Ph.D.</degrees>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Zaretsky</surname>
              <given-names initials="JM">Jesse M.</given-names>
            </name>
            <degrees>B.S.</degrees>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Desrichard</surname>
              <given-names initials="A">Alexis</given-names>
            </name>
            <degrees>Ph.D.</degrees>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Walsh</surname>
              <given-names initials="LA">Logan A.</given-names>
            </name>
            <degrees>Ph.D.</degrees>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Postow</surname>
              <given-names initials="MA">Michael A.</given-names>
            </name>
            <degrees>M.D.</degrees>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Wong</surname>
              <given-names initials="P">Phillip</given-names>
            </name>
            <degrees>Ph.D.</degrees>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Ho</surname>
              <given-names initials="TS">Teresa S.</given-names>
            </name>
            <degrees>B.S.</degrees>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Hollmann</surname>
              <given-names initials="TJ">Travis J.</given-names>
            </name>
            <degrees>M.D., Ph.D.</degrees>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Bruggeman</surname>
              <given-names initials="C">Cameron</given-names>
            </name>
            <degrees>M.A.</degrees>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Kannan</surname>
              <given-names initials="K">Kasthuri</given-names>
            </name>
            <degrees>Ph.D.</degrees>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Li</surname>
              <given-names initials="Y">Yanyun</given-names>
            </name>
            <degrees>M.D., Ph.D.</degrees>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Elipenahli</surname>
              <given-names initials="C">Ceyhan</given-names>
            </name>
            <degrees>B.S.</degrees>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Liu</surname>
              <given-names initials="C">Cailian</given-names>
            </name>
            <degrees>M.D.</degrees>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Harbison</surname>
              <given-names initials="CT">Christopher T.</given-names>
            </name>
            <degrees>Ph.D.</degrees>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Wang</surname>
              <given-names initials="L">Lisu</given-names>
            </name>
            <degrees>M.D.</degrees>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Ribas</surname>
              <given-names initials="A">Antoni</given-names>
            </name>
            <degrees>M.D., Ph.D.</degrees>
          </contrib>
          <contrib contrib-type="author" equal-contrib="yes">
            <name name-style="western">
              <surname>Wolchok</surname>
              <given-names initials="JD">Jedd D.</given-names>
            </name>
            <degrees>M.D., Ph.D.</degrees>
          </contrib>
          <contrib contrib-type="author" equal-contrib="yes">
            <name name-style="western">
              <surname>Chan</surname>
              <given-names initials="TA">Timothy A.</given-names>
            </name>
            <degrees>M.D., Ph.D.</degrees>
          </contrib>
          <aff id="A1">Department of Medicine (A.S., T.M., M.A.P., J.D.W.), Human Oncology and Pathogenesis Program (A.S., V.M., A.D., L.A.W., K.K., T.A.C.), Swim across America–Ludwig Collaborative Research Laboratory (T.M., Y.L., C.E., C.L., J.D.W.), Department of Radiation Oncology (T.A.C.), Department of Pathology (T.J.H.), and Immunology Program, Ludwig Center for Cancer Immunotherapy (J.Y., P.W., T.S.H., J.D.W.), Memorial Sloan Kettering Cancer Center; Weill Cornell Medical College (A.S., M.A.P., J.D.W., T.A.C.); and Department of Mathematics, Columbia University (C.B.) — all in New York; the Department of Molecular and Medical Pharmacology (J.M.Z., A.R.) and the Department of Medicine, Division of Hematology–Oncology, Jonsson Comprehensive Cancer Center (A.R.), University of California, Los Angeles, Los Angeles; and Bristol-Myers Squibb, Princeton, NJ (C.T.H., L.W.).</aff>
        </contrib-group>
        <author-notes>
          <corresp id="CR1">Address reprint requests to Dr. Chan at the Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, 1275 York Ave., Box 20, New York, NY 10065, or at <email>chant@mskcc.org</email>; or to Dr. Wolchok at the Ludwig Center for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center, 1275 York Ave., New York, NY 10065, or at <email>wolchokj@mskcc.org</email>.</corresp>
        </author-notes>
        <pub-date pub-type="epub">
          <day>19</day>
          <month>11</month>
          <year>2014</year>
        </pub-date>
        <pub-date pub-type="ppub">
          <day>4</day>
          <month>12</month>
          <year>2014</year>
        </pub-date>
        <volume>371</volume>
        <issue>23</issue>
        <issue-id pub-id-type="pmc-issue-id">248755</issue-id>
        <fpage>2189</fpage>
        <lpage>2199</lpage>
        <pub-history>
          <event event-type="nihms-submitted">
            <date>
              <day>24</day>
              <month>01</month>
              <year>2015</year>
            </date>
          </event>
          <event event-type="pmc-release">
            <date>
              <day>04</day>
              <month>06</month>
              <year>2015</year>
            </date>
          </event>
          <event event-type="pmc-live">
            <date>
              <day>04</day>
              <month>06</month>
              <year>2015</year>
            </date>
          </event>
          <event event-type="pmc-last-change">
            <date iso-8601-date="2024-06-18 21:25:14.300">
              <day>18</day>
              <month>06</month>
              <year>2024</year>
            </date>
          </event>
        </pub-history>
        <permissions>
          <copyright-statement>Copyright © 2014 Massachusetts Medical Society. All rights reserved.</copyright-statement>
          <copyright-year>2014</copyright-year>
        </permissions>
        <self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="nihms-650831.pdf"/>
        <related-article xmlns:xlink="http://www.w3.org/1999/xlink" related-article-type="commentary" xml:lang="en" xlink:title="article-commentary" vol="371" page="2230" journal-id="N Engl J Med" journal-id-type="nlm-ta" ext-link-type="pmc" xlink:href="PMC4456677">
          <article-title>Somatic Mutations and Immunotherapy Outcome with CTLA-4 Blockade in
Melanoma</article-title>
          <volume>371</volume>
          <issue>23</issue>
          <date>
            <day>19</day>
            <month>11</month>
            <year>2014</year>
          </date>
          <fpage>2230</fpage>
          <lpage>2232</lpage>
          <source>The New England journal of medicine</source>
          <pub-id pub-id-type="pmcid">PMC4456677</pub-id>
          <pub-id pub-id-type="pmid">25409261</pub-id>
        </related-article>
        <abstract>
          <sec id="S1">
            <title>BACKGROUND</title>
            <p id="P1">Immune checkpoint inhibitors are effective cancer treatments, but molecular determinants of clinical benefit are unknown. Ipilimumab and tremelimumab are antibodies against cytotoxic T-lymphocyte antigen 4 (CTLA-4). Anti–CTLA-4 treatment prolongs overall survival in patients with melanoma. CTLA-4 blockade activates T cells and enables them to destroy tumor cells.</p>
          </sec>
          <sec id="S2">
            <title>METHODS</title>
            <p id="P2">We obtained tumor tissue from patients with melanoma who were treated with ipilimumab or tremelimumab. Whole-exome sequencing was performed on tumors and matched blood samples. Somatic mutations and candidate neoantigens generated from these mutations were characterized. Neoantigen peptides were tested for the ability to activate lymphocytes from ipilimumab-treated patients.</p>
          </sec>
          <sec id="S3">
            <title>RESULTS</title>
            <p id="P3">Malignant melanoma exomes from 64 patients treated with CTLA-4 blockade were characterized with the use of massively parallel sequencing. A discovery set consisted of 11 patients who derived a long-term clinical benefit and 14 patients who derived a minimal benefit or no benefit. Mutational load was associated with the degree of clinical benefit (P = 0.01) but alone was not sufficient to predict benefit. Using genomewide somatic neoepitope analysis and patient-specific HLA typing, we identified candidate tumor neoantigens for each patient. We elucidated a neo-antigen landscape that is specifically present in tumors with a strong response to CTLA-4 blockade. We validated this signature in a second set of 39 patients with melanoma who were treated with anti–CTLA-4 antibodies. Predicted neoantigens activated T cells from the patients treated with ipilimumab.</p>
          </sec>
          <sec id="S4">
            <title>CONCLUSIONS</title>
            <p id="P4">These findings define a genetic basis for benefit from CTLA-4 blockade in melanoma and provide a rationale for examining exomes of patients for whom anti–CTLA-4 agents are being considered. (Funded by the Frederick Adler Fund and others.)</p>
          </sec>
        </abstract>
        <custom-meta-group>
          <custom-meta>
            <meta-name>pmc-status-qastatus</meta-name>
            <meta-value>0</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-status-live</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-status-embargo</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-status-released</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-open-access</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-olf</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-manuscript</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-legally-suppressed</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-has-pdf</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-has-supplement</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-pdf-only</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-suppress-copyright</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-is-real-version</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-is-scanned-article</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-preprint</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-in-epmc</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
        </custom-meta-group>
      </article-meta>
    </front>
  </article>
</pmc-articleset>
